$9.33
+ $0.19 (2.08%)
End-of-day quote: 09/24/2022
NasdaqCM:NERV

Minerva Neurosciences (NERV)

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.

With a P/E ratio of 0.00, the stock appears relatively cheap compared to its index ^SPX at the moment.

The market capitalization of Minerva Neurosciences is currently at $0.00 B. This places it among the low capitalized companies.

With one share of Minerva Neurosciences investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.

For the risk analysis, the low beta factor should be noted, which is currently at a value of -0.22. The price of the stock NasdaqCM:NERV is therefore subject to moderate fluctuations in relation to the overall market.

12.23% of NERV Stocks is owned by insiders.

For Wall Street analysts, a price target of $31.00 is currently considered realistic.

NasdaqCM:NERV has a 52 week range of $2.51 - $16.80 and is currently trading around $9.33.

The high short sale ratio indicated that the value might decrease in the foreseeable future.

0
Underperform
1
2
3
4
5
6
7
8
9
10
1M 3M YTD 1Y 2Y 5Y 10Y 20Y
P/E Ratio
0.0
Market Cap
0.00B
LT Debt/Cap
0.00%
Price-to-book Ratio
0
Earnings
11/02/2022
Dividend
$0.00
Div Yld
0.00%
Dividend Growth
0 Years
Beta
-0.22
Short Interest
29.89%
Forecast 1Y
0.00%
Analyst Price Target
$31.00
LTG 5Y
-2440.00%
52 week range
$2.51 - $16.80